Details of the Drug

General Information of Drug (ID: DMIEU69)

• Drug Name: Salmeterol
• Synonyms: Aeromax; Astmerole; SALMATEROL; Salmeterolum; Serevent; Glaxo Wellcome brand of salmeterol xinafoate; Salmeterolum [Latin]; GR 33343X; S 2692; GR-33343X; Serevent (TN); Salmeterol (USAN/INN); Salmeterol [USAN:BAN:INN]; (+-)-4-Hydroxy-alpha'-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol; (+-)-4-Hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol; (inverted question mark) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol; 2-(hydroxymethyl)-4-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-({6-[(4-phenylbutyl)oxy]hexyl}amino)ethyl]phenol; 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol

Indication

Disease Entry	ICD 11	Status	REF
Chronic obstructive pulmonary disease	CA22	Approved	[1], [2]

• Therapeutic Class: Bronchodilator Agents
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 1:
  Molecular Weight (mw); 415.6
  Topological Polar Surface Area (xlogp); 3.9
  Rotatable Bond Count (rotbonds); 16
  Hydrogen Bond Donor Count (hbonddonor); 4
  Hydrogen Bond Acceptor Count (hbondacc); 5
• ADMET Property:
  Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 0.156 mcgh/L [3]
  Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 47.897 ng/L [3]
  Absorption Tmax: The time to maximum plasma concentration (Tmax) is 0.24 h [3]
  BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
  Clearance: The clearance of drug is 392 L/h in asthmatic patients [3]
  Elimination: Salmeterol is 57.4% eliminated in the feces and 23% in the urine, and less than 5% of a dose is eliminated in the urine as unchanged salmeterol [5]
  Half-life: The concentration or amount of drug in body reduced by one-half in 5.5 hours [6]
  Metabolism: The drug is metabolized via the CYP3A4 to alpha-hydroxysalmeterol [6]
  MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.00337 micromolar/kg/day [7]
  Vd: The volume of distribution (Vd) of drug is 177 L [3]
• Chemical Identifiers:
  Formula: C25H37NO4
  IUPAC Name: 2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
  Canonical SMILES: C1=CC=C(C=C1)CCCCOCCCCCCNCC(C2=CC(=C(C=C2)O)CO)O
  InChI: InChI=1S/C25H37NO4/c27-20-23-18-22(13-14-24(23)28)25(29)19-26-15-7-1-2-8-16-30-17-9-6-12-21-10-4-3-5-11-21/h3-5,10-11,13-14,18,25-29H,1-2,6-9,12,15-17,19-20H2
  InChIKey: GIIZNNXWQWCKIB-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 5152
  ChEBI ID: CHEBI:64064
  CAS Number: 89365-50-4
  DrugBank ID: DB00938
  TTD ID: D0L5YV
  INTEDE ID: DR1460

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-2 (ADRB2)	TT2CJVK	ADRB2_HUMAN	Agonist	[8]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4) Main DME	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
Cytochrome P450 3A5 (CYP3A5)	DEIBDNY	CP3A5_HUMAN	Substrate	[10]
Cytochrome P450 3A7 (CYP3A7)	DERD86B	CP3A7_HUMAN	Substrate	[10]

Molecular Expression Atlas of This Drug

• ICD Disease Classification: 12 Disease of the respiratory system
• Disease Class: ICD-11: CA23 Asthma
• The Studied Tissue: Lung tissue
• The Studied Disease: Chronic obstructive pulmonary disease [ICD-11:CA23]

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Adrenergic receptor beta-2 (ADRB2)	DTT	ADRB2	4.88E-01	-0.05	-0.12
Adrenergic receptor beta-2 (ADRB2)	DTT	ADRB2	7.10E-01	0.06	0.09
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	6.74E-01	5.99E-02	7.30E-02
Cytochrome P450 3A5 (CYP3A5)	DME	CYP3A5	3.51E-01	1.59E-01	2.09E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	2.13E-01	4.03E-02	2.50E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	8.21E-02	8.17E-02	4.35E-01

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Salmeterol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Moderate	Additive hypertensive effects by the combination of Salmeterol and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[42]
Ivosidenib	DM8S6T7	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Ivosidenib.	Acute myeloid leukaemia [2A60]	[43]
Midostaurin	DMI6E0R	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Midostaurin.	Acute myeloid leukaemia [2A60]	[43]
Idarubicin	DMM0XGL	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Idarubicin.	Acute myeloid leukaemia [2A60]	[43]
Arn-509	DMT81LZ	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Arn-509.	Acute myeloid leukaemia [2A60]	[43]
Gilteritinib	DMWQ4MZ	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Gilteritinib.	Acute myeloid leukaemia [2A60]	[43]
Oliceridine	DM6MDCF	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Oliceridine.	Acute pain [MG31]	[43]
Ivabradine	DM0L594	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Ivabradine.	Angina pectoris [BA40]	[43]
Bepridil	DM0RKS4	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Bepridil.	Angina pectoris [BA40]	[43]
Dronedarone	DMA8FS5	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Dronedarone.	Angina pectoris [BA40]	[43]
Bedaquiline	DM3906J	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[43]
Cilostazol	DMZMSCT	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Cilostazol.	Arterial occlusive disease [BD40]	[43]
Posaconazole	DMUL5EW	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Posaconazole.	Aspergillosis [1F20]	[43]
Budesonide	DMJIBAW	Minor	Increased risk of hypokalemia by the combination of Salmeterol and Budesonide.	Asthma [CA23]	[44]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[43]
Droxidopa	DM5YF4M	Moderate	Additive hypertensive effects by the combination of Salmeterol and Droxidopa.	Autonomic nervous system disorder [8D87]	[45]
Ofloxacin	DM0VQN3	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[43]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Salmeterol caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[46]
Sparfloxacin	DMB4HCT	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[43]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[43]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[43]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[43]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Salmeterol caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[46]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[43]
Telithromycin	DMZ4P3A	Major	Decreased metabolism of Salmeterol caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[46]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Retigabine.	Behcet disease [4A62]	[43]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Salmeterol caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[47]
Eribulin	DM1DX4Q	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Eribulin.	Breast cancer [2C60-2C6Y]	[43]
Lapatinib	DM3BH1Y	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Lapatinib.	Breast cancer [2C60-2C6Y]	[43]
Tucatinib	DMBESUA	Major	Decreased metabolism of Salmeterol caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[46]
Bosutinib	DMTI8YE	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Bosutinib.	Breast cancer [2C60-2C6Y]	[43]
Corticotropin	DMP9TWZ	Minor	Increased risk of hypokalemia by the combination of Salmeterol and Corticotropin.	Chronic kidney disease [GB61]	[44]
PF-04449913	DMSB068	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[43]
Levomilnacipran	DMV26S8	Moderate	Increased risk of rapid heart rate by the combination of Salmeterol and Levomilnacipran.	Chronic pain [MG30]	[48]
Halothane	DM80OZ5	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Halothane.	Corneal disease [9A76-9A78]	[43]
Sevoflurane	DMC9O43	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Sevoflurane.	Corneal disease [9A76-9A78]	[43]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Probucol.	Coronary atherosclerosis [BA80]	[43]
Pasireotide	DMHM7JS	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Pasireotide.	Cushing syndrome [5A70]	[43]
Sertraline	DM0FB1J	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Sertraline.	Depression [6A70-6A7Z]	[43]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Salmeterol caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[46]
Selegiline	DM6034S	Moderate	Additive hypertensive effects by the combination of Salmeterol and Selegiline.	Depression [6A70-6A7Z]	[42]
Isocarboxazid	DMAF1NB	Moderate	Additive hypertensive effects by the combination of Salmeterol and Isocarboxazid.	Depression [6A70-6A7Z]	[42]
Milnacipran	DMBFE74	Moderate	Increased risk of rapid heart rate by the combination of Salmeterol and Milnacipran.	Depression [6A70-6A7Z]	[48]
Escitalopram	DMFK9HG	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Escitalopram.	Depression [6A70-6A7Z]	[43]
Desvenlafaxine	DMHD4PE	Moderate	Additive hypertensive effects by the combination of Salmeterol and Desvenlafaxine.	Depression [6A70-6A7Z]	[48]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[43]
Deutetrabenazine	DMUPFLI	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Deutetrabenazine.	Dystonic disorder [8A02]	[43]
Ingrezza	DMVPLNC	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Ingrezza.	Dystonic disorder [8A02]	[43]
Solifenacin	DMG592Q	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Solifenacin.	Functional bladder disorder [GC50]	[43]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Salmeterol caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[46]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Salmeterol caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[49]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Salmeterol caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[46]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[43]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Salmeterol caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[46]
Telaprevir	DMMRV29	Major	Decreased metabolism of Salmeterol caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[46]
Procarbazine	DMIK367	Moderate	Additive hypertensive effects by the combination of Salmeterol and Procarbazine.	Hodgkin lymphoma [2B30]	[42]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Salmeterol caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[46]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Salmeterol caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[46]
Saquinavir	DMG814N	Major	Decreased metabolism of Salmeterol caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[46]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[43]
Darunavir	DMN3GCH	Major	Decreased metabolism of Salmeterol caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[46]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Salmeterol caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[50]
Crizotinib	DM4F29C	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Crizotinib.	Lung cancer [2C25]	[43]
Osimertinib	DMRJLAT	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Osimertinib.	Lung cancer [2C25]	[43]
Selpercatinib	DMZR15V	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Selpercatinib.	Lung cancer [2C25]	[43]
Lumefantrine	DM29GAD	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Lumefantrine.	Malaria [1F40-1F45]	[51]
Halofantrine	DMOMK1V	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Halofantrine.	Malaria [1F40-1F45]	[43]
Hydroxychloroquine	DMSIVND	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Hydroxychloroquine.	Malaria [1F40-1F45]	[43]
Primaquine	DMWQ16I	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Primaquine.	Malaria [1F40-1F45]	[43]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[43]
Idelalisib	DM602WT	Major	Decreased metabolism of Salmeterol caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[46]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Salmeterol caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[52]
Arsenic trioxide	DM61TA4	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[43]
Vemurafenib	DM62UG5	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Vemurafenib.	Melanoma [2C30]	[43]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and LGX818.	Melanoma [2C30]	[43]
Panobinostat	DM58WKG	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Panobinostat.	Multiple myeloma [2A83]	[43]
Siponimod	DM2R86O	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Siponimod.	Multiple sclerosis [8A40]	[43]
Fingolimod	DM5JVAN	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Fingolimod.	Multiple sclerosis [8A40]	[43]
Ozanimod	DMT6AM2	Major	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Ozanimod.	Multiple sclerosis [8A40]	[53]
Romidepsin	DMT5GNL	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Romidepsin.	Mycosis fungoides [2B01]	[43]
Nilotinib	DM7HXWT	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Nilotinib.	Myeloproliferative neoplasm [2A20]	[43]
Dasatinib	DMJV2EK	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Dasatinib.	Myeloproliferative neoplasm [2A20]	[43]
Promethazine	DM6I5GR	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Promethazine.	Nausea/vomiting [MD90]	[43]
Entrectinib	DMMPTLH	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Entrectinib.	Non-small cell lung cancer [2C25]	[43]
Sibutramine	DMFJTDI	Moderate	Additive hypertensive effects by the combination of Salmeterol and Sibutramine.	Obesity [5B80-5B81]	[54]
Levomethadyl Acetate	DM06HG5	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Levomethadyl Acetate.	Opioid use disorder [6C43]	[51]
Lofexidine	DM1WXA6	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Lofexidine.	Opioid use disorder [6C43]	[43]
Rucaparib	DM9PVX8	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Rucaparib.	Ovarian cancer [2C73]	[43]
Triclabendazole	DMPWGBR	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Triclabendazole.	Parasitic worm infestation [1F90]	[43]
Safinamide	DM0YWJC	Moderate	Additive hypertensive effects by the combination of Salmeterol and Safinamide.	Parkinsonism [8A00]	[42]
Rasagiline	DM3WKQ4	Moderate	Additive hypertensive effects by the combination of Salmeterol and Rasagiline.	Parkinsonism [8A00]	[42]
Pimavanserin	DMR7IVC	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Pimavanserin.	Parkinsonism [8A00]	[43]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Salmeterol caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[55]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Salmeterol and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[56]
Lefamulin	DME6G97	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Lefamulin.	Pneumonia [CA40]	[43]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Salmeterol caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[46]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Degarelix.	Prostate cancer [2C82]	[43]
ABIRATERONE	DM8V75C	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and ABIRATERONE.	Prostate cancer [2C82]	[43]
Enzalutamide	DMGL19D	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Enzalutamide.	Prostate cancer [2C82]	[43]
Relugolix	DMK7IWL	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Relugolix.	Prostate cancer [2C82]	[43]
Bicalutamide	DMZMSPF	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Bicalutamide.	Prostate cancer [2C82]	[43]
Levomepromazine	DMIKFEL	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Levomepromazine.	Psychotic disorder [6A20-6A25]	[43]
Gatifloxacin	DMSL679	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[43]
Ciclesonide	DM2NA4K	Minor	Increased risk of hypokalemia by the combination of Salmeterol and Ciclesonide.	Respiratory system disease [CB40-CB7Z]	[44]
Dexamethasone	DMMWZET	Minor	Increased risk of hypokalemia by the combination of Salmeterol and Dexamethasone.	Rheumatoid arthritis [FA20]	[44]
Quetiapine	DM1N62C	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Quetiapine.	Schizophrenia [6A20]	[43]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Aripiprazole.	Schizophrenia [6A20]	[46]
Iloperidone	DM6AUFY	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Iloperidone.	Schizophrenia [6A20]	[43]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Paliperidone.	Schizophrenia [6A20]	[43]
Amisulpride	DMSJVAM	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Amisulpride.	Schizophrenia [6A20]	[43]
Asenapine	DMSQZE2	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Asenapine.	Schizophrenia [6A20]	[43]
Pimozide	DMW83TP	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Pimozide.	Schizophrenia [6A20]	[43]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Salmeterol caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[46]
Methylprednisolone	DM4BDON	Minor	Increased risk of hypokalemia by the combination of Salmeterol and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[44]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Salmeterol and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[57]
Triptorelin	DMTK4LS	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[43]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[43]
Pitolisant	DM8RFNJ	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Pitolisant.	Somnolence [MG42]	[43]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[43]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Salmeterol caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[58]
Lenvatinib	DMB1IU4	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Lenvatinib.	Thyroid cancer [2D10]	[43]
Cabozantinib	DMIYDT4	Moderate	Increased risk of prolong QT interval by the combination of Salmeterol and Cabozantinib.	Thyroid cancer [2D10]	[43]
Trimeprazine	DMEMV9D	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[51]
Fluticasone	DMGCSVF	Minor	Increased risk of hypokalemia by the combination of Salmeterol and Fluticasone.	Vasomotor/allergic rhinitis [CA08]	[44]
Procainamide	DMNMXR8	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Procainamide.	Ventricular tachyarrhythmia [BC71]	[43]
Propafenone	DMPIBJK	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Propafenone.	Ventricular tachyarrhythmia [BC71]	[43]
Flecainide	DMSQDLE	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Flecainide.	Ventricular tachyarrhythmia [BC71]	[43]
Amiodarone	DMUTEX3	Moderate	Increased risk of ventricular arrhythmias by the combination of Salmeterol and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[43]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 559).
• [2] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [3] Soulele K, Macheras P, Karalis V: Pharmacokinetic analysis of inhaled salmeterol in asthma patients: Evidence from two dry powder inhalers. Biopharm Drug Dispos. 2017 Oct;38(7):407-419. doi: 10.1002/bdd.2077. Epub 2017 Jul 12.
• [4] BDDCS applied to over 900 drugs
• [5] FDA Approved Drug Products: Serevent Diskus Salmeterol Inhalation Powder
• [6] Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet. 2002;41(1):19-30. doi: 10.2165/00003088-200241010-00003.
• [7] Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
• [8] Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
• [9] Clinical pharmacokinetics of salmeterol. Clin Pharmacokinet. 2002;41(1):19-30.
• [10] Drug Interactions Flockhart Table
• [11] Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
• [12] Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
• [13] Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
• [14] Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
• [15] Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
• [16] Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
• [17] Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
• [18] The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
• [19] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [20] Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
• [21] Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
• [22] Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
• [23] Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
• [24] Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
• [25] Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
• [26] Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
• [27] Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
• [28] The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
• [29] Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
• [30] Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
• [31] The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
• [32] Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
• [33] Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
• [34] Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
• [35] Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9.
• [36] Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
• [37] Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7.
• [38] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [39] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [40] Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75.
• [41] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7353).
• [42] Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology. J Allergy Clin Immunol 75 (1985): 443-9. [PMID: 2858503]
• [43] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
• [44] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
• [45] Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
• [46] Cerner Multum, Inc. "Australian Product Information.".
• [47] Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
• [48] Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
• [49] Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
• [50] Product Information. Severent (salmeterol). Glaxo Wellcome, Research Triangle Park, NC.
• [51] Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
• [52] Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
• [53] Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
• [54] Product Information. Meridia (sibutramine). Knoll Pharmaceutical Company, Whippany, NJ.
• [55] Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
• [56] Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
• [57] Canadian Pharmacists Association.
• [58] Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.